Screener
Fulgent Genetics, Inc. FLGT Therapeutic Development — Sales & Marketing
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
| Three Months Ended March 31, 2026 | Laboratory Services | Therapeutic Development | Total |
|---|---|---|---|
| Revenue | $71,051 | $87 | $71,138 |
| Less: | |||
| Adjusted cost of revenue | 48,179 | 8 | 48,187 |
| Adjusted research and development | 6,461 | 4,178 | 10,639 |
| Adjusted selling and marketing | 11,576 | — | 11,576 |
| Adjusted general and administrative | 20,052 | 357 | 20,409 |
| Total adjusted operating loss | $(15,217) | $(4,456) | $(19,673) |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s therapeutic development — sales & marketing?
- Fulgent Genetics, Inc. (FLGT) reported therapeutic development — sales & marketing of $0 in Q1 2026.
- What does therapeutic development — sales & marketing mean?
- This includes all costs related to the promotion, advertising, and sales efforts for products or services within the therapeutic development segment. It provides insight into the company's investment in market penetration and customer acquisition for its therapeutic offerings.
Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — sales & marketing.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude